Masters of Spin
C15:0 is emerging as the first essential fatty acid to be discovered in over 90 years.
100+ peer-reviewed studies have been published by independent scientists throughout the world on the benefits of C15:0, including the pure C15:0 ingredient in fatty15.
C15:0 is a pleiotropic nutrient with multiple dose-dependent mechanisms of action.
“#1 fastest-growing supplement company and the 5th fastest-growing Consumer Product Company in America on the Inc. 5000 list”
“Evidence of a nutritional C15:0 deficiency - that’s fixable.”
“Cellular Fragility Syndrome” coined by founder.
Cellular Fragility Syndrome = not having enough C15:0 = fix it with fatty15. - with fatty15.
- Our ingredient is officially GRAS (generally regarded as safe) certified, which means fatty15 is safe for pregnant women and nursing moms.
- In our commitment to make fatty15/FA15/C15:0 accessible to all, we have gone above and beyond to enforce the safety of fatty15 for those of all ages and life stages by receiving GRAS (Generally Recognized As Safe) status by the FDA.
No official “GRAS certification” from the FDA. “Certified” implies FDA approval.
“With a recent self-GRAS (Generally Recognized as Safe) affirmation” FA15 can now be used in food and beverage products.
“FA15™ has been approved as a food ingredient that can be used daily, up to 245 mg per day.”
No Public record of evidence used to self-affirm GRAS status.
Deep Dive: Fatty15 vs. Omega-3
“Simply put, fatty15 is better, broader and safer than the purest, highest performing omega-3 (EPA) in repairing and restoring cellular (aka your) health.”
“Fatty15 repairs 2.5x more cell types compared to omega-3.”
“Fatty15 had 36+ cellular benefits across 83% of cell types tested, which was 3x better than omega-3.”
Note: This is a scientific/consumer-protection opinion, not legal advice or an allegation of unlawful conduct.
Unsupported substitution claim. There are no independent, human or animal randomized trials showing C15:0 is superior to EPA/DHA on clinical outcomes; the “3×” claim comes from a single company-affiliated in-vitro screen rather than outcome trials.
Sources: fatty15 “3×” marketing, PLOS ONE in-vitro paper + competing-interest statement
Explicit replacement messaging. The company’s own FAQ says you “may opt to use fatty15 in lieu of omega-3 fish oil supplements.”
Source: fatty15 FAQ
Conflicts with medical consensus. Major authorities advise obtaining EPA/DHA because ALA conversion is limited and fish intake (or Rx EPA) lowers risk in specific populations; telling consumers to replace omega-3s runs counter to that guidance.
Sources: NIH ODS Omega-3 fact sheet, AHA fish/EPA-DHA guidance
Potential for consumer harm. Substitution could dissuade people—especially higher-risk patients—from nutrient and therapies with outcome data (e.g., icosapent ethyl reduces CV events when added to statins).
Sources: NEJM REDUCE-IT trial, FDA label for icosapent ethyl
Likely inadequate substantiation for a comparative health claim. Under FTC standards, comparative efficacy claims require “competent and reliable scientific evidence”—typically well-controlled human studies. An in-vitro screen doesn’t meet that bar.
Source: FTC Health Products Compliance Guidance
Conflicts of interest / non-independence. The in-vitro “3×” paper is authored by company-affiliated inventors with licensed patents; it is not independent and has not been replicated in clinical trials.
Source: PLOS ONE competing-interest statement
Over-extrapolation from cell assays. Cell-panel biomarker differences ≠ clinical benefits in people; dose/exposure relevance and translation are unproven for the claimed endpoints.
Source: PLOS ONE methods/limitations
In my view: borderline unethical. Promoting replacement of EPA/DHA with C15:0 without independent, head-to-head human evidence and against consensus nutrition guidance risks misleading consumers about proven omega-3 benefits.
Is there any human RCT evidence anyway on fatty15???
“Is Fatty15 Legit” Series: Are there clinical trials supporting C15:0 & fatty15 benefits?
“If you’re here, chances are that you recently heard about fatty15, a healthy aging supplement containing C15:0. And you may be wanting to know if this supplement is legit.”
“Are there clinical trials supporting C15:0 & fatty15 benefits?”
“Yes, there are a growing number of clinical trials supporting C15:0 and fatty15’s health benefits.
Here’s a breakdown of the six clinical trials and seven studies to date:”
“Stallings et al. led a clinical trial with healthy humans to determine the oral bioavailability and pharmacokinetics of pure C15:0, the same ingredient provided in fatty15.”
“Participants were provided a single oral dose of C15:0 and showed that circulating C15:0 levels reliably increased.
For every 100 mg of ingested pure free fatty acid C15:0, C15:0 circulating levels increased on average by 1 ug/ml.”
“Mascarenhas et al. then led a clinical trial…to extensively model the oral bioavailability and pharmacokinetics of pure C15:0”
“…repeated findings from the Stallings et al. study. Namely, that
for every 100 mg of ingested pure free fatty acid C15:0, circulating C15:0 levels increased on average by 1 ug/ml.”
“The authors concluded that pure free fatty acid C15:0 is, on average, 100% bioavailable.”
88 Chinese females with NAFLD were randomly assigned to 1 of the 3 groups for 12 wk: diet with C15:0 supplementation (n = 31), diet without C15:0 supplementation (n = 28), or control (habitual diet and no C15:0 supplementation, n = 29). Treatment diet was Asian-adapted Mediterranean diet.
“While all three groups had lowered liver fat and body weight loss, the C15:0 supplemented group trended to having the greatest loss of liver fat and body fat. It is important to note, however, that these shared improvements among all three groups were not statistically significantly between the groups.”
“The authors conclude that C15:0 supplementation had early evidence of providing clinically relevant benefits related to lower LDL cholesterol and an improved gut microbiome.”
List of Metrics unchanged with addition of C15:
Body weight, BMI, Total fat mass, Fat-free mass, Waist circumference,
Visceral adipose tissue (VAT) volume, Subcutaneous abdominal adipose tissue (SAT) volume, Superficial subcutaneous abdominal adipose tissue (SAT), Deep SAT,
Liver fat (MRI-PDFF), Controlled Attenuation Parameter (CAP) score, Intramyocellular lipid (soleus IMCL/water), Pancreatic fat PDFF (head–body), Pancreatic fat PDFF (tail),
Systolic blood pressure, Diastolic blood pressure, Fasting glucose, Fasting insulin, HOMA-IR, HbA1c, Total cholesterol, HDL-cholesterol, Triglycerides,
Gamma-glutamyl transferase (GGT), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), C-reactive protein (CRP), Resting metabolic rate (RMR), Physical activity (steps/day),
Sleep duration,
STAI—State anxiety score, STAI—Trait anxiety score, BDI-II depression score,
Gut microbiome: Bacteroides ovatus abundance, Fusobacterium mortiferum abundance
Total Metrics measured: 37
Metrics unchanged with C15: 36
Metrics changed with C15: 1
*it did on average increase C15 levels
Not a separate clinical trial. Additional data analysis of Trial 4.
“This post-hoc analysis showed that, while all three groups had lower body weight and improved mood, the C15:0 supplemented group had the most significant improvement in mood.
“The authors conclude that C15:0 supplementation may have a positive effect on improving mood.”
Study quotes:
Not on Fatty15 or C15:0 supplementation. It’s on high or moderate dairy fat diets. Much less relevant.
“Clinical Trial 6: Arghavani et al. led a cross-over clinical trial that included healthy adults to evaluate the potential effects of dairy fat diets, as well as individual fatty acid components within dairy fat, on blood pressure and vascular stiffness”. “This clinical trial showed the following:”
The 2025 paper by Arghavani et al. is a secondary analysis of data from an already‐conducted randomized crossover trial.
There is nothing in the original RCT about C15.
Original RCT - “Objective: The aim of this clinical trial was to evaluate the impact of high dairy product intake (HD) (≥4 servings/d) for 6 wk, compared with an adequate dairy product intake (AD) (≤2 servings/d), on glycemic and insulinemic parameters, insulin sensitivity, insulin secretion, and β-cell function in hyperinsulinemic adults.”
“Kaneko et al. led a randomized, placebo-controlled clinical trial that included older women to evaluate the potential effects of an oral high-C15 algal oil on skin elasticity, collagen density, and skin moisture. This clinical trial showed that daily oral intake of high-C15 algal oil for 12 weeks improved skin elasticity, collagen density, and skin moisture.”
“The authors conclude that oral intake of high C15-containing supplements provides skin health benefits.”
Orlan oil, containing C:15 but also many other fatty acids like DHA, DPA, EPA.
Dose of C15 per day: ~9mg
Of the 6 “clinical trials supporting C15:0 or fatty15 benefits”:
The only RCT in humans on actual on Fatty15.
“Robinson et al. led a randomized, double-blinded and placebo-controlled clinical trial with young adults (ages 18 to 24 years old) at risk of metabolic syndrome and who were purposely avoiding whole fat dairy products”
Among participants who adhered to the protocol, their C15:0 levels increased at the same amounts demonstrated by Mascarenhas et al. and Stallings et al.
Namely, 200 mg of C15:0 resulted in raised circulating C15:0 levels of 2.3 ug/ml.”
“C15:0 levels increased among participants who strictly adhered to the protocol.”
Reverse logic: Groups were formed after the study, based on final C15:0 levels, not on adherence.
Only half reached the threshold
Adherence per group:
Change in plasma C15:0 levels from baseline to 12 wk
Half of those on fatty15, taking on average 84.3% of pills (152 total) did not raise C15:0 levels above threshold.
“Among participants who adhered to the protocol, their C15:0 levels increased…This group with raised C15:0 levels also had significantly improved liver function (lower ALT and AST)”
Study Abstract:
“Half of the participants in the treatment group had a posttreatment C15:0 level >5 μg/mL. In these individuals, there were significantly greater decreases in alanine aminotransferase (−29 U/L, P = 0.001) and aspartate aminotransferase (−6 U/L, P = 0.014), as well as a greater increase in hemoglobin (0.60 g/dL, P = 0.010), as compared with participants that did not reach a posttreatment level >5 μg/mL.”
“significantly greater decreases in alanine aminotransferase (−29 U/L, P = 0.001) and aspartate aminotransferase (−6 U/L, P = 0.014), as well as a greater increase in hemoglobin (0.60 g/dL, P = 0.010), as compared with participants that did not reach a posttreatment level >5 μg/mL.”
List of Metrics unchanged with addition of C15:
Body weight, BMI, Waist circumference, Hip circumference,
Systolic blood pressure, Diastolic blood pressure,
Fasting glucose, Fasting insulin,
Total cholesterol, HDL cholesterol, LDL cholesterol, Triglycerides,
C-reactive protein (CRP), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Hemoglobin
Total Metrics measured: 17
Metrics unchanged with fatty15: 16
Metrics changed with fatty15: 1
*it did on average increase C15 levels
What the skeptics say
In videos, skeptics go over two clinical trials (Robinson et al. and Chooi et al.) and incorrectly conclude that these trials were not in relevant populations and did not demonstrate efficacy.
Strangely, the skeptics made these statements while showing the papers’ abstracts, where the authors themselves concluded that C15:0 demonstrated promising results.
The skeptics do not mention any of the other five studies and four clinical trials provided above, in part because two are recent publications.
but if you still want to try fatty15:
To recreate the study doses: (based on 90 day subscription)
What are you paying for? Marketing!
Fatty15: Another Subscription!
“Essential fatty acid” / widespread deficiency
Not supported: C15:0 is not recognized as essential by authorities. Sources: NIH ODS (EFAs = LA & ALA), Company blog
The 3 authors of the study claijmming this are: Founder of fatty15, financed by Epitracker (Venn-Watson owned company), and a scientific advisor to fatty15 who holds equity in the company.
“Cellular Fragility Syndrome”
Not supported: Not a recognized medical diagnosis (absent from ICD-11, not a MeSH descriptor). The term is introduced by company-affiliated authors in a single hypothesis/review and amplified in marketing/press; there is no independent clinical validation or diagnostic criteria. See the hypothesis paper (Venn-Watson 2024), company blog (fatty15), and third-party critique (CSPI).
Metabolic health (PPAR-α/δ, AMPK, mitochondria)
Not supported (human RCTs): 12-wk placebo-controlled trials raised blood C15:0 but no between-group improvements in clinical endpoints except small LDL decrease (1/37), and very very weak “subgroup” analysis for lower AST/ALT.
Sources: J Nutr RCT (2024)
Heart health (LDL; cardiometabolic risk/events)
Neutral/insufficient: No trials show fewer CVD events; observational meta-analysis shows no association with all-cause mortality and non-significant pooled associations for some CVD subtypes for 15:0.
Sources: PLOS Med meta-analysis (2021)
Liver health (enzymes; fatty liver)
Not supported (human): 12 week human RCT trial showed no difference in liver Fat, or liver enzymes (except GGT, (but not in subgroup, lower ALT/AST in subgroup)) Unclear results (placebo increased GGT). Sources: J Nutr RCT, AJCN TANGO RCT (2024)
Red blood cells (membranes; hemoglobin)
Neutral (human ITT): Hemoglobin increase seen only in NON-RANDOM subgroup, not vs placebo in intention-to-treat.
Source: J Nutr RCT
Immune health / inflammation (cytokines, CRP)
Not supported (human): No human RCT showing reductions; both human RCTs showed no difference in CRP in C15 group.
Cognitive & mental health (dopamine/PPAR; mood/stress)
Insufficient (human): No human trials located; claims are marketing. RCT they claim supports this (not RCT, secondary anlaysis of RCT), authors state “The present study cannot conclude that the group receiving C+15:0 together with the MD had effects in decreasing symptoms.” Example claim: Company blog
Sleep quality
Insufficient (human): No C15:0 sleep RCTs; “deeper sleep” appears in marketing/surveys. RCT found do difference in sleep duration. Example claim: Product page
Hunger/satiety (PPAR-α)
Insufficient (human): No RCTs measuring appetite/energy intake/GLP-1/ghrelin.
Example claim: Company post
Joint comfort
Insufficient (human): No human RCTs on joint pain/function.
Example claim: Marketing copy
Gut microbiome
Limited/neutral (human): In NAFLD (TABGO) trial, Bifidobacterium adolescentis increase reported with C15:0, but no broader microbiome “health” or clinical GI benefits established.
Source: AJCN TANGO RCT
Anti-aging / “slows and reverses aging”
Not supported (human outcomes): No trials on aging endpoints or epigenetic clocks; mortality association for 15:0 is null in meta-analysis.
Sources: PLOS Med meta-analysis, Homepage claim, “Reversing cellular aging” blog
“Reduces mTOR” (longevity mechanism)
Insufficient (human): Based on mechanistic/cell work, not human outcomes.
Sources: Company mTOR blog, Review asserting AMPK↑/mTOR↓ is written by author and of questionable relevance.
“3× more cellular benefits than EPA (omega-3)” / “take fatty15 instead of omega-3”
Not supported (human); potentially misleading—arguably borderline unethical. The “3×” figure comes incorrect math from a single in-vitro screen by company-affiliated authors; there are NO human RCTs or animal RCTs showing clinical superiority over EPA. Substitution messaging (implying you should take fatty15 instead of omega-3) conflicts with established recommendations that EPA/DHA remain important nutrients. Comparative health claims promoting substitution away from EPA/DHA conflicts with consensus guidance and, without competent and reliable human evidence, should be backed by competent and reliable scientific evidence, typically well-controlled human trials—which is not present here, a concern under FTC health-claims standards.
Sources: Company claim, FTC Health Products Compliance Guidance, NIH ODS: Omega-3, AHA: Fish & omega-3
Note: This is a scientific/consumer-protection opinion, not legal advice or an allegation of unlawful conduct.